Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand

Executive Summary

US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.

Advertisement

Related Content

Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
J&J Forges Ahead In Immunology Despite Competitive Dynamics
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel